Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Resectable Oral Cavity SCC
NCT03784066Phase 2Active, not recruiting
- Sponsor
- UZ Leuven
- Start
- Aug 2018
- Primary completion
- Mar 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in oral cavity squamous cell carcinoma (OCSCC), sponsored by UZ Leuven. Started Aug 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT03784066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784066.